R&D channel feed – Endpoints News

R&D channel feed

Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data

8 years ago

University was tipped off to possible unauthorized trials of herpes vaccine

8 years ago

Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model

8 years ago

Pharma's broken business model: An industry on the brink of terminal decline

8 years ago

Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study

8 years ago

Strike two: Auris shares crushed again as its second PhIII program fails to deliver

8 years ago

Roiled by financial turmoil, Teva's CEO boots R&D chief, top execs in C-suite overhaul

8 years ago

Catalyst heads back to the FDA in search of an elusive OK after Firdapse scores high in new PhIII

8 years ago

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

8 years ago

Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers

8 years ago

Teva R&D chief out as new CEO picks up the ax and aims at deep cuts to rescue a faltering biopharma — report

8 years ago

Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab

8 years ago

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

8 years ago

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

8 years ago

Cytokinetics axes lead drug after it implodes in a PhIII muscle trial for ALS, shares crater

8 years ago

Ardelyx scraps PhIII drug after researchers raise a safety issue for hyperkalemia patients

8 years ago

Bayer AG taps PeptiDream in billion-dollar deal

8 years ago

Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths

8 years ago

Roche shares surge as a double-shot win in I/O and hemophilia raises blockbuster expectations

8 years ago

Fearless: Julian Adams looks to steer Gamida Cell through PhIII, an IPO and a market launch

8 years ago

Struggling Oncolytics Biotech signs $86.6M Asia deal with China's Adlai Nortye

8 years ago

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH?

8 years ago

FDA, EMA put a star CAR-T from bluebird and Celgene on the VIP list

8 years ago

Not your mom’s probiotic: GV-backed Evelo teams up with Mayo Clinic on microbiome drugs

8 years ago

First page Previous page 285 286 287288289 290 291 Next page Last page